Cimavax-EGF, an epidermal growth factor (EGF)-targeting vaccine approved in Cuba for non-small cell lung cancer (NSCLC), extended median survival from 6 months to >5 years in responders by neutralizing EGF and inhibiting tumor proliferation [97]. The gene discussed is EGF; the disease is non-small cell lung carcinoma.